Eli Lil­ly claims a TKO in its long-run­ning ti­tle fight with No­vo Nordisk for the block­buster di­a­betes mar­ket — but there’s a hitch

Eli Lil­ly isn’t just gun­ning for a bet­ter di­a­betes drug in tirzepatide. They want to cut ahead of No­vo Nordisk’s block­buster ri­val Ozem­pic (semaglu­tide) on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.